TransMedics (TMDX) Cash from Financing Activities (2018 - 2026)

TransMedics' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $3.8 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 24.24% year-over-year to $3.8 million in Q1 2026; TTM through Mar 2026 was $17.6 million, a 22.56% decrease from a year earlier, with the FY2025 full-year figure at $16.9 million, down 26.3% from the prior year.
• Cash from Financing Activities climbed to $3.8 million in Q1 2026 per TMDX's latest filing, from $3.1 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $394.0 million in Q2 2023 and bottomed at $237000.0 in Q2 2022.
• The 5-year median for Cash from Financing Activities is $3.2 million (2024), against an average of $36.0 million.
• Biggest YoY gain for Cash from Financing Activities was 166150.21% in 2023; the steepest drop was 99.07% in 2023.
• Year by year, Cash from Financing Activities stood at $3.1 million in 2022, then slumped by 69.85% to $924000.0 in 2023, then rose by 28.35% to $1.2 million in 2024, then soared by 161.3% to $3.1 million in 2025, then advanced by 21.39% to $3.8 million in 2026.
• Per Business Quant, the three latest TMDX Cash from Financing Activities figures stand at $3.8 million (Q1 2026), $3.1 million (Q4 2025), and $3.6 million (Q3 2025).